Bisphosphonate therapy in metastatic breast cancer

Acta Oncologica

Volumn 35, Issue SUPPL. 5, 1996, Pages 81-83

  Blomqvist, Carl ^a   Elomaa, Inkeri ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; MEDRONIC ACID; PAMIDRONIC ACID;

ADULT; AGED; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FRACTURE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS; CLODRONIC ACID; DIPHOSPHONATES; HUMANS;

EID: 0030483389     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609083977     Document Type: Article

References (17)

1. Mundy GR, Ibbotsón KJ, D'Souza SM, et al. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med 1984; 310(26): 1718-27.
2. Elomaa I, Blomqvist C. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Acta Oncologica 1995; 34: 629-636.
3. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. Analysis of 1000 cases. Cancer 1950; 3: 74-95.
4. Kamby C, Ejlertsen B, Andersen J, et al. The pattern of metastases in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. Acta Oncol 1988; 27(6A): 715-9.
5. Paterson AH. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 1987;.
6. Stewart AF, Vignery A, Silverglate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982; 55(2): 219-27.
7. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 1991; 42: 919-944.
8. Elomaa I, Blomqvist C, Grohn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; 1(8317): 146-9.
9. Elomaa I, Blomqvist C, Porkka L, et al. Diphosphonates for osteolytic metastases [letter]. Lancet 1985; 1(8438): 1155-6.
10. Conte PF, Giannessi PG, Latreille J, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 1994; 5 Suppl 7:S41-4.
11. Martoni A, Guaraldi M, Camera P, et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 1991; 48(2): 97-101.
12. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
13. van Holten Verzantvoort A, Kroon HM, Bijvoet OL, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11(3): 491-8.
14. Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983; 74(3): 401-6.
15. van Holten Verzantvoort A, Bijvoet OL, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; 2(8566): 983-5.
16. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: A double-blind placebo-controlled study. J Clin Oncol 1995; 13: 2427-2430.
17. Paterson AHG. Treatment of breast cancer with no bone involvement. Second workshop on Bisphosphonates. Davos, 1994.